I-MED Pharma Set to Launch its Dry Eye Product Portfolio in the US

I-MED Pharma USA announced it is bringing its dry eye product portfolio to the US market and will sell directly to eye care professionals.

The dry eye portfolio includes I-DROP artificial tears, I-LID ’N LASHocular hygiene cleansers, I-DEFENCE night-time dry eye ointment, I-VUOMEGA-3 nutritional supplements, I-RELIEF therapeutic mask, and the E>Eye IRPL device specifically designed to treat evaporative dry eye due to meibomian gland dysfunction.

The latest innovation is I-DROP MGD, a preservative-free, viscoadaptive eye drop containing a lipid designed to enhance and stabilize all three layers of the tear film. Its unique formulation contains osmoprotectants and bioprotectants which help to relieve symptoms in patients suffering from chronic evaporative dry eye disease. I-DROP MGD is available in a multi-dose bottle with a sophisticated one-way valve and air-return system that delivers one sterile-dosed drop at a time.

“We look forward to partnering with eye care professionals in the US to offer our highly effective products to their patients suffering from dry eye disease. Our unique and innovative products are formulated and perfected through years of research and development and can truly be a game-changer for dry eye sufferers," Philipp Binder, President and Chief Operations Officer of I-MED Pharma, said in a company news release. "Our mission is to bring complete relief to dry eye and ocular surface disease patients worldwide and this expansion into the United States brings us one step closer to achieving that.”